Why this matters: NIH-funded basic research has an outsized influence on private sector R&D priorities. Research shows that every dollar of public investment in basic science generates over eight dollars in additional industry R&D spending within a decade.[1] This makes NIH funding patterns a leading indicator—and forcing function—for where biotechnology companies will invest. By analyzing recent grant portfolios, we can identify both the most promising research directions and the critical gaps where translation is lagging.
NIH funds extensive research documenting how environmental exposures cause harm, and separately funds biotech research developing disease treatments. But there's a translation gap: the mechanisms connecting exposure to disease are rarely targeted for preventive intervention.
Environmental exposure grants (2022-2025): 6,752 verified grants (~2% of NIH portfolio) study chemicals, pollutants, diet, infections, and lifestyle factors as risk factors for disease. Of these, 5,119 explicitly studied biological mechanisms of harm and are shown in the Sankey diagram on the left.
Biotech grants (2021-2024): ~18,000 grants were categorized by therapeutic modality (gene therapy, immunotherapy, cell therapy, etc.) and mapped to the 11 mechanisms of harm. Cell counts in the heatmap reflect grants relevant to each mechanism—some grants appear under multiple mechanisms. These represent research that could address environmental damage but currently focuses on disease treatment rather than prevention.
Key findings: Strong biotech investment exists for receptor/signaling pathways, neurodegeneration, epigenetics, and immune dysfunction, all mechanisms with clear therapeutic targets. The biggest gaps: oxidative stress lacks dedicated therapeutic modalities, barrier repair research is underdeveloped, and microbiome and inflammation remain underexplored relative to their central role in exposure-driven pathology.
Click mechanisms or heatmap cells to explore translation opportunities and gaps